GlassScriptPhysician profile
Tziporah Kay
NPI 1225674393
$14,905.18
in general payments reported to CMS, 2019-2025
43 companies · $3,345 in 2025
The $3,345 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,199 · 2022: $1,900 · 2023: $4,695 · 2024: $3,766 · 2025: $3,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,748 · Travel and Lodging: $1,849 · Education: $197 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,748.39 |
| Travel and Lodging | $1,849.29 |
| Education | $197.42 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,275.57 | 2023-2024 | Infinity, Proclaim |
| Teva Pharmaceuticals USA, INC. | $1,890.44 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $1,248.45 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $1,246.98 | 2021-2025 | Nuplazid, Daybue |
| Amneal Pharmaceuticals LLC | $1,033.09 | 2021-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Mdd US Operations, LLC | $963.68 | 2021-2025 | Gocovri, Gocovri |
| Ucb, INC. | $643.71 | 2021-2025 | Briviact, Nayzilam, Rystiggo |
| Alnylam Pharmaceuticals INC. | $579.43 | 2022-2025 | Amvuttra |
| Neurocrine Biosciences, INC. | $569.87 | 2021-2025 | Ingrezza, Ongentys |
| Merz Pharmaceuticals, LLC | $563.12 | 2021-2025 | Xeomin, Inbrija |
| Otsuka America Pharmaceutical, INC. | $426.96 | 2023-2025 | Rexulti, Nuedexta |
| Lundbeck LLC | $304.94 | 2024-2025 | Vyepti |
| Eisai INC. | $280.50 | 2022-2025 | |
| Lilly USA, LLC | $256.55 | 2023-2025 | Amyvid, Emgality, Kisunla |
| Xeris Pharmaceuticals, INC. | $232.53 | 2023-2025 | Keveyis |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $225.88 | 2022-2025 | Gamunex-C |
| Biogen, INC. | $210.83 | 2022-2025 | Leqembi, Vumerity, Tysabri |
| Allergan, INC. | $207.44 | 2021-2022 | |
| Avion Pharmaceuticals | $184.14 | 2022-2023 | Dhivy |
| Argenx US, INC. | $167.96 | 2024-2025 | Vyvgart Hytrulo |
| Sk Life Science, INC. | $163.86 | 2023-2025 | |
| Genzyme Corporation | $157.12 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $145.34 | 2021-2025 | Ultomiris |
| Neurelis, INC. | $110.12 | 2023-2025 | Valtoco |
| Sunovion Pharmaceuticals INC. | $105.98 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $98.03 | 2023-2025 | Dysport |
| Pfizer INC. | $96.60 | 2024-2025 | |
| Emd Serono, INC. | $70.33 | 2023-2025 | |
| Csl Behring | $62.14 | 2021-2023 | Kcentra, Hizentra |
| Biohaven Pharmaceuticals, INC. | $52.71 | 2021 | |
| Kyowa Kirin, INC. | $46.49 | 2024 | Nourianz |
| Biohaven Pharmaceutical Holding Company LTD. | $39.18 | 2022 | |
| Janssen Biotech, INC. | $31.91 | 2025 | |
| Genentech USA, INC. | $31.75 | 2024 | Ocrevus |
| Life Molecular Imaging LTD | $25.36 | 2025 | Neuraceq |
| Springworks Therapeutics, INC. | $24.58 | 2025 | Gomekli |
| Amgen INC. | $22.17 | 2025 | Uplizna |
| Tanabe Pharma America, INC. | $21.78 | 2022 | |
| Scilex Pharmaceuticals INC. | $19.32 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.10 | 2024 | |
| Boston Scientific Corporation | $18.74 | 2024 | |
| Octapharma USA, INC. | $15.42 | 2023 | Panzyga |
| Almatica Pharma LLC | $15.08 | 2023 | Gralise |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tziporah Kay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.